Caitlin A Murphy1, Kathleen V Fitch1, Meghan Feldpausch1, Patrick Maehler1, Kimberly Wong1, Martin Torriani2, Gail K Adler3, Steven K Grinspoon1, Suman Srinivasa1. 1. Program in Nutritional Metabolism, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Division of Musculoskeletal Imaging and Intervention, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
Purpose: Natriuretic peptides (NPs) negatively feedback on the renin-angiotensin-aldosterone system (RAAS) and play a critical role in preserving cardiac structure and maintaining metabolic homeostasis. Well-treated HIV-infected individuals are at risk for fat redistribution and demonstrate evidence of RAAS dysregulation, which relates to metabolic dysfunction. We investigated circulating NPs in relation to RAAS physiology and metrics of body composition in HIV. Methods: We assessed atrial natriuretic peptide, brain natriuretic peptide (BNP), and amino terminal pro B-type natriuretic peptide (NT-proBNP) during acute activation of the RAAS using a low-sodium controlled diet among 20 HIV-infected and 10 non-HIV-infected individuals well phenotyped for body composition. Results: BNP was significantly lower [median, 60 (interquartile range, 44, 152) pg/mL vs 196 (91, 251) pg/mL, respectively; P = 0.04], and serum aldosterone was higher, among HIV-infected than among non-HIV-infected individuals. BNP was significantly and inversely associated with body composition [waist circumference: r = -0.46 (P = 0.04); BMI: r = -0.55 (P = 0.01); body adiposity index: r = -0.49 (P = 0.03)], metabolic indices [total cholesterol: r = -0.44 (P = 0.05), insulin resistance calculated by using homeostatic model assessment: r = -0.44 (P = 0.05); mean arterial pressure: r = -0.44 (P = 0.05)], and serum aldosterone (r = -0.49; P = 0.03) among the HIV-infected group. These relationships were not demonstrated in the non-HIV-infected group. In a four-group comparison stratifying by HIV serostatus and above or below a body mass index (BMI) of 25 kg/m2, BNP decreased significantly across groups; it was highest in non-HIV-infected patients with a BMI <25 kg/m2 and lowest in HIV-infected patients with a BMI ≥25 kg/m2 (overall P = 0.01). Conclusion: Relatively reduced NP, particularly BNP, among HIV-infected individuals with excess adiposity may contribute to reduced suppression of aldosterone and potentially drive aldosterone-mediated metabolic complications. Strategies that target RAAS blockade and/or augment NPs may be useful to reduce cardiometabolic disease among HIV-infected individuals in whom these systems are perturbed.
Purpose: Natriuretic peptides (NPs) negatively feedback on the renin-angiotensin-aldosterone system (RAAS) and play a critical role in preserving cardiac structure and maintaining metabolic homeostasis. Well-treated HIV-infected individuals are at risk for fat redistribution and demonstrate evidence of RAAS dysregulation, which relates to metabolic dysfunction. We investigated circulating NPs in relation to RAAS physiology and metrics of body composition in HIV. Methods: We assessed atrial natriuretic peptide, brain natriuretic peptide (BNP), and amino terminal pro B-type natriuretic peptide (NT-proBNP) during acute activation of the RAAS using a low-sodium controlled diet among 20 HIV-infected and 10 non-HIV-infected individuals well phenotyped for body composition. Results:BNP was significantly lower [median, 60 (interquartile range, 44, 152) pg/mL vs 196 (91, 251) pg/mL, respectively; P = 0.04], and serum aldosterone was higher, among HIV-infected than among non-HIV-infected individuals. BNP was significantly and inversely associated with body composition [waist circumference: r = -0.46 (P = 0.04); BMI: r = -0.55 (P = 0.01); body adiposity index: r = -0.49 (P = 0.03)], metabolic indices [total cholesterol: r = -0.44 (P = 0.05), insulin resistance calculated by using homeostatic model assessment: r = -0.44 (P = 0.05); mean arterial pressure: r = -0.44 (P = 0.05)], and serum aldosterone (r = -0.49; P = 0.03) among the HIV-infected group. These relationships were not demonstrated in the non-HIV-infected group. In a four-group comparison stratifying by HIV serostatus and above or below a body mass index (BMI) of 25 kg/m2, BNP decreased significantly across groups; it was highest in non-HIV-infectedpatients with a BMI <25 kg/m2 and lowest in HIV-infectedpatients with a BMI ≥25 kg/m2 (overall P = 0.01). Conclusion: Relatively reduced NP, particularly BNP, among HIV-infected individuals with excess adiposity may contribute to reduced suppression of aldosterone and potentially drive aldosterone-mediated metabolic complications. Strategies that target RAAS blockade and/or augment NPs may be useful to reduce cardiometabolic disease among HIV-infected individuals in whom these systems are perturbed.
Authors: Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett Journal: Hypertension Date: 2014-11-03 Impact factor: 10.190
Authors: Richard N Bergman; Darko Stefanovski; Thomas A Buchanan; Anne E Sumner; James C Reynolds; Nancy G Sebring; Anny H Xiang; Richard M Watanabe Journal: Obesity (Silver Spring) Date: 2011-03-03 Impact factor: 5.002
Authors: Jagdeep S S Singh; Louise M Burrell; Myriam Cherif; Iain B Squire; Andrew L Clark; Chim C Lang Journal: Heart Date: 2017-07-08 Impact factor: 5.994
Authors: Inder S Anand; Brian Claggett; Jiankang Liu; Amil M Shah; Thomas S Rector; Sanjiv J Shah; Akshay S Desai; Eileen O'Meara; Jerome L Fleg; Marc A Pfeffer; Bertram Pitt; Scott D Solomon Journal: JACC Heart Fail Date: 2017-04 Impact factor: 12.035
Authors: Kathleen V Fitch; Christopher DeFilippi; Robert Christenson; Suman Srinivasa; Hang Lee; Janet Lo; Michael T Lu; Kimberly Wong; Eva Petrow; Laura Sanchez; Sara E Looby; Udo Hoffmann; Markella Zanni; Steven K Grinspoon Journal: AIDS Date: 2016-09-10 Impact factor: 4.177
Authors: Pankaj Arora; Jason Reingold; Aaron Baggish; Derek P Guanaga; Connie Wu; Anahita Ghorbani; Yanna Song; Annabel Chen-Tournaux; Abigail May Khan; Laurel T Tainsh; Emmanuel S Buys; Jonathan S Williams; Denise M Heublein; John C Burnett; Marc J Semigran; Kenneth D Bloch; Marielle Scherrer-Crosbie; Christopher Newton-Cheh; Lee M Kaplan; Thomas J Wang Journal: J Am Heart Assoc Date: 2015-01-16 Impact factor: 5.501
Authors: Wei Wu; Fubiao Shi; Dianxin Liu; Ryan P Ceddia; Robert Gaffin; Wan Wei; Huafeng Fang; E Douglas Lewandowski; Sheila Collins Journal: Sci Signal Date: 2017-07-25 Impact factor: 8.192
Authors: Grace Shen; Teressa S Thomas; Allie R Walpert; Colin M McClure; Kathleen V Fitch; Christopher deFilippi; Martin Torriani; Colleen G Buckless; Gail K Adler; Steven K Grinspoon; Suman Srinivasa Journal: Clin Endocrinol (Oxf) Date: 2022-06-06 Impact factor: 3.523
Authors: Suman Srinivasa; Teressa S Thomas; Meghan N Feldpausch; Gail K Adler; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2021-11-19 Impact factor: 5.958
Authors: Sepiso K Masenga; Fernando Elijovich; John R Koethe; Benson M Hamooya; Douglas C Heimburger; Sody M Munsaka; Cheryl L Laffer; Annet Kirabo Journal: Curr Hypertens Rep Date: 2020-09-03 Impact factor: 5.369
Authors: Barbara Thorand; Martin Reincke; Cornelia Then; Katrin Ritzel; Christian Herder; Holger Then; Chaterina Sujana; Margit Heier; Christa Meisinger; Annette Peters; Wolfgang Koenig; Wolfgang Rathmann; Michael Roden; Haifa Maalmi; Michael Stumvoll; Thomas Meitinger; Martin Bidlingmaier; Jochen Seissler Journal: BMJ Open Diabetes Res Care Date: 2022-01